

ODP COVID-19 Vaccination Update

February 2, 2021

As of 2/1/2021

World Cases: 103,244,127

World Deaths: 2,233,610

United States Cases: 26,231,939

United States Deaths: 442,399

02/01/2021

Confirmed Cases

736,236

Probable Cases


109,842

Negative Tests

3,646,648

Deaths

21,687



Cases per 100,000 Population


0 - 4,500 > 4,500 - 5,500 > 5,500 - 6,500 > 6,500 - 7,500 > 7,500

Information last updated at 12:00 noon on 02/01/2021. Case count data, map and new cases per day data from PA-NEDSS. Deaths by day graph data from EDRS.


New Cases Per Day



Deaths by Day



Daily PCR Tests




*Case Counts in the charts above include confirmed and probable cases

Date of Data Extraction 1/27/2021

Cumulative COVID-19 Data ID/A Community System Including Private ICFs


	Individuals				Staff	
ODP Region	COVID-19 Suspected	COVID-19 Confirmed	Tested Negative	Deaths	COVID-19 Suspected	COVID-19 Confirmed
Southeast	289	1,491	695	116	1,780	1,879
Northeast	194	612	332	28	1,886	1,040
Central	287	618	305	26	2,612	1,027
Western	390	976	805	67	3,902	1,680
Statewide Total	1,160	3,697	2,137	237	10,180	5,626

Statewide Confirmed Individual and Staff COVID-19 Cases



COVID-19 Interim Vaccination Plan Prioritization

Version: Jan 19, 2021



Major Updates:

- As recommended by Operation Warp Speed on 1/12/21 adds individuals ages 65 and older and
- Individuals ages 16-64 with certain underlying medical conditions in Phase 1A.
- Updated list of underlying conditions in-line with CDC (now includes Down Syndrome and Sickle Cell Disease)
- Added in 1A Healthcare Personnel “individuals providing services for the elderly and persons with disabilities including unpaid caregivers”

COVID-19 Interim Vaccination Plan Prioritization

Version: Jan 19, 2021

Phase 1A

- Long Term Care Facilities: Residents and staff of community group homes and ICFs
- Healthcare Personnel: All DSPs supporting individuals through face-to-face service provision outside of an ICF or 6400 setting are included in Phase 1A;
- Healthcare Personnel: individuals providing services for the elderly and persons with disabilities including unpaid caregivers

Phase 1B

- Individuals receiving home and community-based services
 - Office of Developmental Programs Home and Community-Based Services

Phase 1A

- Cancer
- Chronic kidney disease
- COPD
- Down Syndrome
- Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
- Immunocompromised state (weakened immune system)
- Obesity (body mass index [BMI] of 30 kg/m² or higher but < 40 kg/m²)
- Severe Obesity (BMI ≥ 40 kg/m²)
- Pregnancy
- Sickle cell disease
- Smoking
- Type 2 diabetes mellitus

Vaccination Distribution

- **1A Healthcare Personnel – Non-residential DSPs**
 - 12/30/2020 SoH Order – 10% set aside by hospitals, health systems, Federally Qualified Health Centers (FQHCs), and pharmacies for vaccination of Phase 1A non-hospital affiliated health care personnel – includes DSPs from non-residential settings
 - Provider should coordinate with vaccine provider from the listed contact information on DOHs [website](#).
 - DSPs will need to provide proof of occupation

Vaccination Distribution

- **1A Long Term Care Facilities**
 - Federal Pharmacy Partnership for eligible facilities – CVS and Walgreens
 - State Centers
 - ICFs
 - Enrolled Licensed 6400 homes
 - PA DHS Pharmacy Partnership – Rite Aid
 - Licensed 6400s
 - On-site for homes that have residents who need vaccination on-site
 - Local vaccination clinics for staff and residents
 - Vaccine Provider (staff only)
 - Hospitals, health systems, Federally Qualified Health Centers (FQHCs), and pharmacies for vaccination of Phase 1A non-hospital affiliated health care personnel

- Myths and Facts from the University of Missouri Health Care site
- [The COVID-19 Vaccine: Myths vs. Facts \(muhealth.org\)](#)

**Myth: The COVID-19
vaccine is unsafe
because it was
developed so quickly.**

- **Fact:** The vaccine is proven safe and effective. Although it was developed in record time, it has gone through the same rigorous Food and Drug Administration process as every other vaccine, meeting all safety standards. No steps were skipped. Instead, we can thank the unprecedented worldwide collaboration and investment for the shorter timeframe on the development of the vaccine itself. The clinical trials and safety reviews actually took about the same amount of time as other vaccines.

**Myth: The COVID-19
vaccine will alter my
DNA.**

- **Fact:** The first vaccines granted emergency use authorization contain messenger RNA (mRNA), which instructs cells to make the “spike protein” found on the new coronavirus. When the immune system recognizes this protein, it builds an immune response by creating antibodies — teaching the body how to protect against future infection. The mRNA never enters the nucleus of the cell, which is where our DNA (genetic material) is kept. The body gets rid of the mRNA soon after it’s finished using the instructions.

**Myth: The COVID-19
vaccine includes a
tracking device.**

- **Fact:** A video shared thousands of times on Facebook makes false claims about the products of syringe maker Apiject Systems of America, which has a contract with the government to provide medical-grade injection devices for vaccines. The company has an optional version of its product that contains a microchip within the syringe label that helps providers confirm a vaccine dose's origin. The chip itself is not injected into the person getting the vaccine.

Myth: The COVID-19 vaccine has severe side effects such as allergic reactions.

Fact: Some participants in the vaccine clinical trials did report side effects similar to those experienced with other vaccines, including muscle pain, chills and headache. And although extremely rare, people can have severe allergic reactions to ingredients used in a vaccine. That's why experts recommend people with a history of severe allergic reactions — such as anaphylaxis — to the ingredients of the vaccine should not get the vaccination.

Myth: I've already been diagnosed with COVID-19, so I don't need to receive the vaccine.

Fact: If you have already had COVID-19, there's evidence that you can still benefit from the vaccine. At this time, experts don't know how long someone is protected from getting sick again after recovering from COVID-19. The immunity someone gains from having an infection, called natural immunity, varies from person to person. Some early evidence suggests natural immunity may not last very long.

**Myth: Once I receive
the COVID-19 vaccine,
I no longer need to
wear a mask.**

Fact: Masking, handwashing and physical distancing remain necessary until a sufficient number of people are immune. The best protection we can offer each other right now is to continue to follow current guidelines. As more people are vaccinated and experts have a better idea of how long natural and vaccine immunity last, public health experts will update their guidance as necessary.

**Myth: You can get
COVID-19 from the
vaccine.**

Fact: You cannot get COVID-19 from the vaccine because it doesn't contain the live virus.

Myth: Once I receive the vaccine, I will test positive for COVID-19.

Fact: Viral tests used to diagnose COVID-19 check samples from the respiratory system for the presence of the virus that causes COVID-19. Since there is no live virus in the vaccines, the vaccines will not affect your test result. It is possible to get infected with the virus before the vaccine has had time to fully protect your body.

**Myth: I'm not at risk for
severe complications of
COVID-19 so I don't
need the vaccine.**

Fact: Regardless of your risk, you can still contract the infection and spread it to others, so it's important you get vaccinated. Once the vaccine is widely available, it's recommended that as many eligible adults as possible get the vaccine. It's not only to protect you but your family and community as well.

COVID-19 vaccine trials by the numbers

As of November 30, 2020

Pfizer/BioNTech

- **43,931** enrolled
- **150** clinical sites
 - 39 U.S. states
- Racial/ethnic distribution
 - **13%** - Hispanic
 - **10%** - African American
 - **6%** - Asian
 - **1%** - Native American
- **45%** ages 56-85

Sources: <https://www.pfizer.com/science/coronavirus/vaccine>;

<https://www.modernatx.com/cove-study>

For more information, visit www.clinicaltrials.gov

Moderna

- **30,000** enrolled
- **89** clinical sites
 - 32 U.S. states
- Racial/ethnic distribution
 - **63%** - White
 - **20%** - Hispanic
 - **10%** - African American/Black
 - **4%** - Asian
 - **3%** - All others
- **64%** ages 45 and older
 - 39% ages 45-64
 - 25% ages 65+



About these COVID-19 mRNA vaccines

- These mRNA vaccines are expected to produce side effects after vaccination, especially after the 2nd dose.
 - Side effects may include:
 - Fever
 - Headache
 - Muscle aches
- No significant safety concerns were identified in the clinical trials.



Source: <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19/clinical-considerations.html>

Helping to reduce the spread of COVID-19



- Wash your hands with soap and water for at least 20 seconds or use hand sanitizer if soap and water are not available.
- Cover any coughs or sneezes with your elbow, not your hands.
- Clean surfaces frequently.
- Stay home to avoid spreading COVID-19, especially if you are unwell.
- If you must go out, you are required to wear a mask when in a business or where it is difficult to maintain proper social distancing.
- Download the COVID Alert PA app and make your phone part of the fight.

Resources

Resources for Individuals and Families

- <https://aidinpa.org/>
- Forthcoming updates will include:
 - Spanish language materials
 - ASL videos added as clickable links within the social stories and one pager
 - One pager parallel document meeting accessibility needs for low visual acuity
 - Animations to convey social stories
 - Informational updates, as approved by DOH Vaccine Team



Resources for Providers: Resources for Preparing for Vaccinating Staff/Residents

- [PENNSYLVANIA DEPARTMENT OF HEALTH 2020 – PAHAN – 541-12-16-ADV](#): Infection prevention and control considerations for healthcare personnel with signs and symptoms following COVID-19 vaccination
- [PENNSYLVANIA DEPARTMENT OF HEALTH 2020 – PAHAN – 542- ADV– 12-19](#): Infection prevention and control considerations for residents of long-term care facilities with signs and symptoms following COVID-19 vaccination

Resources for Providers: Preparing for Vaccinating Staff/Residents

Webinar: COVID-19 Vaccine: Information & Best Practices

Hear from experts and peers regarding vaccine education and implementation strategies.

<https://pittsburghregionalhealth.webex.com/pittsburghregionalhealth/lsr.php?RCID=d5c500be54a355aaa3d4eba07e1f2323>

